Compare HAL & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAL | TEVA |
|---|---|---|
| Founded | 1919 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8B | 30.2B |
| IPO Year | 2006 | N/A |
| Metric | HAL | TEVA |
|---|---|---|
| Price | $33.88 | $31.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $34.25 | ★ $37.38 |
| AVG Volume (30 Days) | ★ 10.9M | 6.0M |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $17,973,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.69 | $2.51 |
| P/E Ratio | $42.10 | ★ $28.19 |
| Revenue Growth | ★ 22.47 | N/A |
| 52 Week Low | $18.72 | $12.47 |
| 52 Week High | $37.03 | $37.35 |
| Indicator | HAL | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 31.79 |
| Support Level | $32.81 | $30.70 |
| Resistance Level | $35.55 | $31.99 |
| Average True Range (ATR) | 1.13 | 0.95 |
| MACD | -0.28 | -0.42 |
| Stochastic Oscillator | 21.53 | 5.68 |
Halliburton is North America's largest oilfield-services company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. Halliburton's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been honed over a century of operations.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.